In a cross-sectional study of 300 older Indian adults (mean age 67.6 years) with type 2 diabetes and controlled fasting glucose, those screening positive for sarcopenia risk via the SARC-F questionnaire showed postprandial blood glucose excursions averaging 119.4 mg/dL above fasting — versus 74.8 mg/dL in low-risk individuals, a 44.6 mg/dL gap (95% CI 36.8–52.5, p<0.0001). Each one-point rise in SARC-F score independently predicted a 10.2 mg/dL higher post-meal glucose rise after adjusting for age, diabetes duration, fasting glucose, and medication regimen. The correlation coefficient was striking at r=0.777.
This finding carries real clinical weight. Skeletal muscle accounts for roughly 70–80% of insulin-stimulated glucose disposal; when muscle mass erodes, the post-meal glucose sink shrinks regardless of how well fasting glucose is managed. This helps explain why HbA1c can look deceivingly acceptable while postprandial spikes — the glycemic fraction most strongly linked to cardiovascular risk — remain dangerous. The implication for adults over 50 with T2DM is direct: resistance training, which builds the glucose sink, may be as pharmacologically important as adjusting secretagogues. Limitations are substantial, however. This is a single-centre, cross-sectional design in an Indian outpatient population using a screening tool rather than gold-standard muscle measurement, so causality cannot be established. Being a preprint not yet peer-reviewed, methodology and conclusions require independent validation before influencing clinical practice. Still, the mechanistic framing — treating sarcopenia as a metabolic, not merely a mobility, problem — is a meaningful reorientation.